Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Rhizome serves as an AI regulatory collaborator specifically designed for teams in the life sciences sector. While general AI assistants offer remarkable capabilities, there are distinct requirements for an AI tool that aids in making decisions regarding drugs or devices worth over $100 million.
Our agents are strictly limited to referencing facts derived from primary source documents, ensuring that nothing is validated based on agent memory; we assess their performance based on this criterion, and there have been no instances of inaccuracies reported in the past 18 months.
The databases that underpin regulatory decisions, including Drugs@FDA, guidance documents, clinicaltrials.gov, and various standards, often exist in formats that are not easily searchable by computers, with a significant amount being image-only PDFs. We have developed the ability to ingest and process all of this information, encompassing over 75 health authority databases across more than 12 markets as of August 2026, with this number continually growing. This equates to over 45 million documents that our agents can query comprehensively.
In contrast to a general assistant, which typically references 5 to 10 sources, Rhizome is capable of examining hundreds to thousands of documents, as the essential question is often, "Did we overlook a precedent?" This thorough approach ensures that our users are equipped with the most comprehensive and accurate information possible.
Description
eSpear has developed a name recognition search engine that draws upon the extensive expertise of former intelligence professionals, whose primary responsibility was to sift through enormous data sets to pinpoint only the “bad actors.” The engine is specifically designed to match the transaction processing rates of its users, ensuring seamless operation during critical events such as Cyber Monday in the US, Singles Day in China, major global sporting events, election days worldwide, and automated currency trading. With decades of specialized knowledge integrated into its design, eSpear achieves an impressive reduction in false positives, recording rates of just 0.5% during initial screenings and an even lower 0.05% on subsequent checks, while successfully identifying “bad actors” that other search engines fail to detect. This unmatched level of precision places eSpear far ahead of its competitors in the market. As a result, clients can trust in the reliability and accuracy of eSpear's capabilities, making it an invaluable tool in the fight against fraudulent activities.
API Access
Has API
No
API Access
Has API
No
Integrations
ChatGPT
No
Claude
No
Microsoft 365 Copilot
No
Pricing Details
$0/month/user
Free Trial
No
Free Version
Yes
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
Yes
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
Yes
Online Support
No
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Vendor Details
Company Name
Rhizome AI
Founded
2023
Country
United States
Website
rhizomeai.com
Vendor Details
Company Name
eSpear
Country
United States
Website
espear.com
Product Features
Product Features
Compliance
Archiving & Retention
Yes
Artificial Intelligence (AI)
No
Audit Management
Yes
Compliance Tracking
No
Controls Testing
No
Environmental Compliance
No
FDA Compliance
No
HIPAA Compliance
No
ISO Compliance
No
Incident Management
No
OSHA Compliance
No
Risk Management
Yes
Sarbanes-Oxley Compliance
No
Surveys & Feedback
No
Version Control
No
Workflow / Process Automation
No